Table 1 Demographics details, clinical data, and laboratory data. Results are reported as n (%) or median (IQR)
Death at 1 year | Total (N = 153) | ||
|---|---|---|---|
No (N = 67) | Yes (N = 86) | ||
Age (years) | 60.00 (38.50–68.50) | 63.00 (50.25–70.00) | 61 (46–69) |
Male | 45 (67.2) | 60 (69.8) | 105 (69) |
G6PD deficiency | 7 (10.4) | 2 (2.3) | 9 (6) |
Underlying malignancy | |||
Solid cancer | 0 (0) | 2 (2.3) | 2 (1) |
Leukemia | 23 (34.3) | 29 (33.7) | 52 (34) |
Non-Hodgkin lymphoma | 38 (56.7) | 52 (60.5) | 90 (59) |
Multiple myeloma | 2 (3.0) | 0 (0) | 2 (1%) |
Other | 4 (6.0) | 3 (3.5) | 7 (5%) |
Spontaneous TLS | 34 (50.7) | 56 (65.1) | 90 (59) |
Risk of TLS | |||
Low risk | 9 (13.4) | 15 (17.4) | 24 (16) |
Intermediate risk | 5 (7.5) | 4 (4.7) | 9 (6) |
High risk | 53 (79.1) | 67 (77.9) | 120 (78) |
Cardiovascular risk | |||
Chronic hypertension | 19 (28.4) | 27 (31.4) | 46 (30.1) |
Diabetes | 7 (10.4) | 12 (14.0) | 19 (12.4) |
Cardiovascular event | 5 (7.5) | 10 (11.6) | 15 (9.8) |
Chronic kidney disease | 6 (9.2) | 4 (4.7) | 10 (6.6) |
HIV positive status | 7 (10.4) | 19 (22.1) | 26 (17) |
SOFA score | 5.00 (3.00–8.00) | 7.50 (5.00–12.00) | 6.5 (4–9) |
Vasopressors | 1 (1.5) | 21 (36) | 24 (16) |
Mechanical ventilation | 5 (7.5) | 29 (33.7) | 34 (22.2) |
Rasburicase use | 54 (80.6) | 60 (69.8) | 114 (75) |
Laboratory data at admission | |||
Kalemia, mEq/L | 4.60 (4.00–5.00) | 4.30 (3.90–5.00) | 4.3 (3.9–5.0) |
Phosphatemia, mg/dL | 4.59 (3.61–6.08) | 4.19 (3.08–5.94) | 4.45 (3.41–5.88) |
Calcemia, mg/dL | 8.94 (7.90–9.50) | 8.50 (7.84–9.45) | 8.80 (8–9.60) |
Uricemia, mg/dL | 8.96 (5.64–13.10) | 7.49 (5.12–12.16) | 8.46 (5.23–12.41) |
LDH, UI/L | 2700 (1544–5168) | 2855 (1544–5263) | 2819 (1533–5169) |
Delay admission-chemotherapy (days) | 1 (0–7) | 4 (0.5–12) | 2.5 (0–11) |
ICU mortality | 0 (0) | 27 (31.4) | 27 (18) |
One-year remission | 54 (80.6) | 0 (0.0) | 54 (35.3) |